Associated Papers
Germline mutations predispose a concurrent thymoma and diffuse large B-cell lymphoma.
Fu X et al.
Annals of Hematology, 2025
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R et al.
Signal Transduction and Targeted Therapy, 2023
37032379 (PubMed )
Supplement: 41392_2023_1358_MOESM4_ESM.xlsx › __
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L et al.
Blood Advances, 2022
34654055 (PubMed )
Supplement: advancesADV2021006034-suppl1.pdf
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J et al.
Frontiers in Immunology, 2022
35572515 (PubMed )
Supplement: Table_2.xlsx › S5
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
Yasuda T et al.
Cancer Science, 2020
32619037 (PubMed )
Supplement: CAS-111-3367-s004.xlsx › Sup.Table4
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
32736575 (PubMed )
Supplement: 12885_2020_7198_MOESM5_ESM.xlsx › Table_S3
An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.
Cherian MA et al.
The Journal of Biological Chemistry, 2018
Select a paper to view details